- Home
- MCRI vs PRCT Comparison
MCRI vs PRCT Comparison
Compare MCRI & PRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MCRI | PRCT |
|---|---|---|
| Founded | 1972 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.5B |
| IPO Year | 1996 | 2021 |
Fundamental Metrics
Financial Performance| Metric | MCRI | PRCT |
|---|---|---|
| Price | $96.44 | $25.12 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 11 |
| Target Price | ★ $100.50 | $35.44 |
| AVG Volume (30 Days) | 95.2K | ★ 1.4M |
| Earning Date | 04-21-2026 | 04-23-2026 |
| Dividend Yield | ★ 1.24% | N/A |
| EPS Growth | ★ 41.41 | 1.71 |
| EPS | ★ 5.43 | N/A |
| Revenue | ★ $395,377,000.00 | $308,054,000.00 |
| Revenue This Year | $4.85 | $31.34 |
| Revenue Next Year | $2.21 | $24.52 |
| P/E Ratio | $17.78 | ★ N/A |
| Revenue Growth | ★ 114.40 | 37.22 |
| 52 Week Low | $69.99 | $19.35 |
| 52 Week High | $113.88 | $64.89 |
Technical Indicators
Market Signals| Indicator | MCRI | PRCT |
|---|---|---|
| Relative Strength Index (RSI) | 49.75 | 45.02 |
| Support Level | $94.35 | $19.35 |
| Resistance Level | $99.51 | $29.06 |
| Average True Range (ATR) | 3.05 | 1.42 |
| MACD | -0.33 | 0.03 |
| Stochastic Oscillator | 64.64 | 22.27 |
Price Performance
Historical ComparisonAbout MCRI Monarch Casino & Resort Inc.
Monarch Casino & Resort Inc is engaged in providing the latest gaming, dining, and hospitality amenities. It owns and operates the Atlantis Casino Resort Spa, a hotel/casino facility in Reno, Nevada, and the Monarch Black Hawk Casino in Black Hawk. The company generates the majority of its revenue from Casinos, followed by Food & Beverage and Hotel Operations.
About PRCT PROCEPT BioRobotics Corporation
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, which are image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.